Human Immunodeficiency Virus Polymorphisms and Zidovudine Resistance

Stürmer et al. presented an interesting paper (1) on the influence of the classic zidovudine (ZDV) mutation patterns and the role of the additional mutations at positions 208, 211, 214, and 333 on phenotypic ZDV resistance. The presence of the 211/214 mutation combination in the background of genotypic highly ZDV-resistant viruses increased ZDV resistance 2.4-fold, and the 208/211/214 combination increased ZDV resistance 8-fold. The authors suspect a stabilization mechanism of the three-dimensional structure of the enzyme that could be explained by the vicinity of the mutations at positions 208, 211, and 214 to the ZDV-associated mutations L210W and T215Y/F. These mutations are likely involved in the compensation of the possible loss of fitness caused by the T215Y/F mutation.

We investigated the drug susceptibility of human immunodeficiency virus (HIV) strains of 19 HIV-infected patients failing double nucleoside reverse transcriptase inhibitor (NRTI) therapy by using the genotypic and the phenotypic assays. We identified four patterns of genotypic resistance (Table 1), namely, pattern 1, in patients with the 184V mutation alone; pattern 2, in patients with the 184V mutation combined with the 208Y, 211K, and/or 214F mutations; pattern 3, in patients with the 184V mutation and thymidine analogue mutations (TAMs) (including 41L, 210W, 215Y/F, and/or 219Q/E); and pattern 4, in patients with TAMs and the 184V mutation combined with the 208Y, 211K, and/or 214F mutations. As expected, genotypic patterns 1 and 3 showed a phenotypic resistant pattern to lamivudine (3TC) alone and to both 3TC and ZDV, respectively. The presence of 208/211/214 polymorphism combined with the 184V mutation (genotypic pattern 2) was related to a high phenotypic cross-resistance within all NRTIs analyzed. The presence of TAMs in addition to this pattern (genotypic pattern 4) showed a reduced phenotypic resistance for stavudine (d4T) and, to a smaller extent, for didanosine, ZDV, and abacavir.

The impact of the 208/211/214 polymorphism in terms of NRTI drug susceptibility on a background of a resistant virus appears to be related to the presence of the 184V mutation alone. High cross-resistance to all NRTIs has been detected only in HIV strains with this polymorphism combined with the 184V mutation in absence of TAMs. This particular genotypic-phenotypic pattern was detected among patients treated with stavudine (d4T) and, to a smaller extent, for didanosine, (genotypic pattern 4) showed a reduced phenotypic resistance for stavudine (d4T) and, to a smaller extent, for didanosine, ZDV, and abacavir.

TABLE 1. Pattern of genotypic and phenotypic resistance of 19 HIV strains of patients failing double NRTI therapy

| Pattern of genotypic mutation(s)* | No. of samples | No. of samples with phenotypic resistance (IC50 range [fold])#
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>184V</td>
<td>4</td>
<td>d4T: 0 (0.6–1.1) 3TC: 4 (22–1,666) dd1: 0 (0.8–1.7) AZT: 0 (0.4–2) ABC: 2 (1.1–30)</td>
</tr>
<tr>
<td>184V and TAMs</td>
<td>3</td>
<td>d4T: 0 (0.5–2.1) 3TC: 3 (132–235) dd1: 1 (1.1–8) AZT: 3 (5.4–200) ABC: 1 (0.7–11.6)</td>
</tr>
<tr>
<td>184V and 208Y/211K/214I and TAMs</td>
<td>8</td>
<td>d4T: 2 (0.6–182) 3TC: 8 (14–542) dd1: 4 (1–53) AZT: 5 (0.9–940) ABC: 6 (0.9–276)</td>
</tr>
</tbody>
</table>

* TAMs include 41L, 210W, 215Y/F, and/or 219Q/E mutation(s).
# d4T, didanosine; ABC, abacavir.

Therefore, we reanalyzed our database, which has been expanded to evaluate the significance of this polymorphism in the clinical outcome of patients treated with highly active antiretroviral therapy.

REFERENCE


Emanuele Nicastri
Istituto Nazionale per le Malattie Infettive
IRCCS L. Spallanzani
Rome, Italy

Loredana Sarmati
Massimo Andreoni*
Istituto di Malattie Infettive
Università di Roma
Tor Vergata
Via Montepellier 1
00133 Rome, Italy

Saverio G. Parisi
Istituto di Malattie Infettive
Università di Verona
Verona, Italy

*Phone: 390672596873
Fax: 390672596873
E-mail: andreoni@uniroma2.it

Authors’ Reply

Nicastri and colleagues investigated drug susceptibility of HIV type 1 strains isolated from 19 patients using both genotypic and phenotypic assays. They identified four mutational patterns and analyzed the corresponding phenotypes. One mutational pattern including the M184V, H208Y, R211K, and/or 214F mutations is likely to be related to the presence of different pathways in the emergence of NRTI resistance mutations in HIV-infected patients failing a d4T-3TC or ZDV-3TC regimen. Longitudinal studies are needed to

 downloadable from http://aac.asm.org/ on March 25, 2021 by guest
tended in the meantime, and found only two samples (2 of 2,331) from one patient with the mutational pattern described by Nicastri and colleagues (M184V, H208Y, R211K, and/or L214F without TAMs). We have submitted this sequence to two virtual phenotype-based interpretation systems, Geno2Pheno (1) and VirtualPhenotype (Virco) (2). The following results were obtained for Geno2Pheno (obtained fold change in the 50% inhibitory concentration [IC₅₀]/cutoff): zidovudine, 1.6/8.5; didanosine and zalcitabine, 2.1/2.5; stavudine, 1.4/2.5; lamivudine, 68.6/8.5; and abacavir, 2.9/2.5. Similar results were found using VirtualPhenotype (obtained IC₅₀ fold change/cutoff): zidovudine, 0.9/4.0; didanosine, 1.2/2.0; zalcitabine, 1.5/2.0; stavudine, 0.7/1.8; lamivudine, 46.0/4.5; and abacavir, 1.6/3.0. In the case of VirtualPhenotype, the IC₅₀ fold changes were calculated using a median of 2,714 matches in the database (range, 1,102 to 2,924). When a sample with only the M184V mutation was analyzed in the VirtualPhenotype system, a similar pattern of IC₅₀ fold changes was obtained.

These findings don’t support a broad cross-resistance in the group of NRTIs produced by the above-mentioned mutational pattern. The slightly increased IC₅₀ fold changes observed for didanosine, zalcitabine, and abacavir are associated with the presence of the M184V change (3) independent of other polymorphisms but could not be interpreted as broad cross-resistance to these drugs. The patient isolates with the mutational pattern described as conferring NRTI cross-resistance by Nicastri and colleagues should be reanalyzed in consideration of the presence of known multidrug resistance patterns or other mutational patterns yet uncharacterized. Furthermore, the principle of the phenotypic assay used should be made available, and the samples should be retested to clarify these contrary findings.

REFERENCES


Martin Stürmer*
Hans-Wilhelm Doerr
Institut für Medizinische Virologie
J. W. Goethe Universität
Paul Ehrlich Straße 40
60596 Frankfurt, Germany

Schlomo Staszewski
Zentrum der Inneren Medizin
J. W. Goethe Universität
Paul Ehrlich Straße 40
60596 Frankfurt, Germany

Kurt Hertogs
Tibotec-Virco NV
Mechelen, Belgium

*Phone: 49 69 6301 6454
Fax: 49 69 6301 6477
E-mail: M.Stuermer@em.uni-frankfurt.de